News
The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...
A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.
The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.
A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who ...
Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.
Pharmalittle: We’re reading about a Moderna flu vaccine, a J&J loss over 340B rebate plans, and more
Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...
From relentless claim denials and payer pressures to policy debates around prior authorization and the 340B program, this mid-year briefing unpacks the six essential stories every revenue cycle leader ...
Johnson & Johnson failed to convince a federal judge that the US government acted unlawfully when it rejected the company’s ...
The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the ...
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s law on 340B pricing for contract pharmacy ...
The American Hospital Association and three other healthcare organizations have filed an amicus brief defending Tennessee’s 340B contract pharmacy law, which is facing a challenge from the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results